Larimar Therapeutics, Inc.

Report azionario NasdaqGM:LRMR

Capitalizzazione di mercato: US$340.3m

Larimar Therapeutics Gestione

Criteri Gestione verificati 2/4

Larimar Therapeutics Il CEO è Carole Ben-Maimon, nominato in May2020, e ha un mandato di 6.17 anni. la retribuzione annua totale è $ 3.53M, composta da 18.4% di stipendio e 81.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.11% delle azioni della società, per un valore di $ 376.90K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6 anni e 6 anni.

Informazioni chiave

Carole Ben-Maimon

Amministratore delegato

US$3.5m

Compenso totale

Percentuale dello stipendio del CEO18.43%
Mandato del CEO6.2yrs
Proprietà del CEO0.1%
Durata media del management6yrs
Durata media del Consiglio di amministrazione6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Jun 30

Larimar Therapeutics: Late-Stage FA Program Advances Amid Execution Risks

Summary Larimar Therapeutics has initiated a rolling BLA submission for nomlabofusp, supported by encouraging pre-BLA feedback and a potential mid-2027 launch. I have a Hold rating on LRMR due to execution risks around confirmatory Phase 3 data and commercial implications from the observed safety profile. LRMR's financials show a solid $200M cash position and disciplined cost control, but a cash runway only into 2Q27, making clinical and regulatory milestones critical. Nomlabofusp’s open-label data show promising biomarker and clinical trends, but small sample size, high anaphylaxis rates, and high discontinuation rates temper enthusiasm. Read the full article on Seeking Alpha
Articolo di analisi • Jan 24

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • May 28

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jan 03

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Summary Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels from 15% to 30%. The global Friedreich's Ataxia market size is projected to reach $2.06 billion by 2030. Additional data using higher 50 mg dose of nomlabofusp to treat patients with Friedreich's Ataxia expected in mid-2025. Accelerated Approval BLA filing of nomlabofusp for patients with Friedreich's Ataxia might be possible 2nd half of 2025 on basis of a surrogate biomarker endpoint of FXN protein levels. Read the full article on Seeking Alpha
Articolo di analisi • Dec 18

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Oct 07

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Summary Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a solid cash runway, sufficient liquidity, and trades at reasonable valuations compared to its upside potential. LRMR's favorable Phase 1/2 trial results bolster CTI-1601's approval odds, with a potential Biologics License Application submission by 2H2025. Additionally, CTI-1601 has multiple FDA and EU designations, potentially expediting its development and approval process. Despite competition risks, LRMR's unique approach and sufficient resources make it a speculative "Buy" for investors aware of inherent biotech risks. Read the full article on Seeking Alpha
Articolo di analisi • Aug 09

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 15

Larimar Therapeutics: More Data Still Needed

Summary Larimar Therapeutics' stock has surged 50% after its FA therapy was selected for FDA's START program, aiming for a BLA filing in 2H25. Its lead candidate Nomlabofusp is a protein replacement therapy for Friedreich's ataxia, competing with Biogen's Skyclarys and other potential treatments. Larimar has enough cash to fund operations until 2026, with analyst optimism and a timeline to potentially beat competitors to the market. Can the recent rally in the shares continue? A full investment analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • May 31

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Summary Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that the global Friedreich's Ataxia market could reach $2.06 billion by 2030. Interim data from the ongoing phase 2 open-label study, using nomlabofusp for the treatment of patients with Friedreich's Ataxia, expected Q4 of 2024. Nomlabofusp for the treatment of patients with Friedreich's Ataxia selected as part of the FDA pilot program known as START, which is intended to accelerate the development of drugs that target rare unmet medical needs. Read the full article on Seeking Alpha
Articolo di analisi • Nov 13

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • May 19

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Articolo di analisi • Feb 02

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 20

Laramar Therapeutics issued patent for lead pipeline candidate

Larimar Therapeutics (NASDAQ:LRMR) has been granted a composition of matter patent covering CTI-1601, its lead pipeline candidate for Friedreich’s ataxia. The patent provides coverage through at least July 2040. CTI-1601, currently in phase 1, has Fast Track and Orphan Drug designation from the US FDA. The company plans to begin a phase 2 trial for CTI-1601 by the end of the year. Seeking Alpha's Quant Rating views Larimar (LRMR) as a strong buy with high marks for momentum and revisions.
Seeking Alpha • Sep 14

Larimar Therapeutics prices ~$70M stock offering

Larimar Therapeutics (NASDAQ:LRMR) has priced of an underwritten offering of 22,225,000 shares of common stock at $3.15 per share. Underwriters have been granted a 30-day overallotment option to purchase up to 3,333,750 additional shares of common stock at the offering price. Gross proceeds to Larimar (LRMR) are expected to be ~$70M. The offering is expected to close around Sep 16, 2022. The biotech company also received FDA clearance to initiate the 25mg cohort of a Phase 2 Dose exploration trial of its lead compound, CTI-1601, in Friedreich's ataxia patients. It plans to begin the Phase 2 trial in Q4 2022, with top-line data expected in 2H 2023. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich's ataxia who are unable to produce enough of this essential protein. LRMR shares have gained 2% pre-market on the news
Articolo di analisi • Sep 02

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 11

Larimar Therapeutics GAAP EPS of -$0.47

Larimar Therapeutics press release (NASDAQ:LRMR): Q2 GAAP EPS of -$0.47. Cash and marketable debt securities at June 30, 2022 of $54.9 million provides projected cash runway through the third quarter of 2023
Articolo di analisi • Mar 21

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Dec 18

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Feb 08

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Carole Ben-Maimon rispetto agli utili di Larimar Therapeutics?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$166m

Dec 31 2025US$4mUS$650k

-US$166m

Sep 30 2025n/an/a

-US$132m

Jun 30 2025n/an/a

-US$100m

Mar 31 2025n/an/a

-US$95m

Dec 31 2024US$3mUS$600k

-US$81m

Sep 30 2024n/an/a

-US$65m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$3mUS$560k

-US$37m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$2mUS$528k

-US$35m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$2mUS$510k

-US$51m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$49m

Mar 31 2021n/an/a

-US$48m

Dec 31 2020US$5mUS$268k

-US$42m

Compensazione vs Mercato: La retribuzione totale di Carole ($USD 3.53M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.47M ).

Compensazione vs guadagni: La retribuzione di Carole è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Carole Ben-Maimon (67 yo)

6.2yrs
Mandato
US$3,526,423
Compensazione

Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Carole Ben-Maimon
CEO, President & Director6.2yrsUS$3.53m0.11%
$ 376.9k
Michael Celano
Secretary & CFO6.2yrsUS$1.70m0.11%
$ 384.4k
Gopi Shankar
Chief Development Officer3.4yrsUS$1.29m0.021%
$ 72.0k
John Berman
Vice President of Finance & Administration2.9yrsNessun datoNessun dato
Jennifer Johansson
Vice President of Legal & Compliance9.6yrsNessun datoNessun dato
Russell Clayton
Chief Medical Officer3yrsNessun dato0.068%
$ 232.9k
Francis Conway
VP & Controller6yrsNessun datoNessun dato
6.0yrs
Durata media
66yo
Età media

Gestione esperta: Il team dirigenziale di LRMR è esperto e expertise (durata media dell'incarico 6 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Carole Ben-Maimon
CEO, President & Director6.2yrsUS$3.53m0.11%
$ 376.9k
Jonathan Leff
Independent Director6.2yrsUS$74.90k0%
$ 0
Jeffrey Sherman
Independent Director2.8yrsUS$66.15k0.0048%
$ 16.3k
Frank Thomas
Independent Director12.1yrsUS$82.40k0.0067%
$ 22.8k
Thomas Hamilton
Independent Director6.2yrsUS$73.65k0.79%
$ 2.7m
Joseph Truitt
Independent Chairman of the Board6.2yrsUS$109.90k0.0026%
$ 8.9k
Giovanni Manfredi
Member of Scientific Advisory Board5.8yrsNessun datoNessun dato
Mark Payne
Member of Scientific Advisory Board5.8yrsNessun datoNessun dato
Marni Falk
Member of Scientific Advisory Board5.8yrsNessun datoNessun dato
Jill Ostrem
Member of Scientific Advisory Board3.8yrsNessun datoNessun dato
6.0yrs
Durata media
59.5yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di LRMR sono considerati esperti (durata media dell'incarico 6 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/06 08:20
Prezzo dell'azione a fine giornata2026/07/06 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Larimar Therapeutics, Inc. è coperta da 15 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
null nullBaird
Christopher ChenBaird
Joel BeattyBaird